Browse

CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features

DC Field Value Language
dc.contributor.authorPark, Seog-Yun-
dc.contributor.authorKook, Myeong Cherl-
dc.contributor.authorKim, Young Woo-
dc.contributor.authorCho, Nam-Yun-
dc.contributor.authorKwon, Hyeong-Ju-
dc.contributor.authorKang, Gyeong Hoon-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorJung, Namhee-
dc.date.accessioned2012-06-27T09:02:22Z-
dc.date.available2012-06-27T09:02:22Z-
dc.date.issued2010-10-
dc.identifier.citationVIRCHOWS ARCHIV; Vol.457 4; 415-422ko_KR
dc.identifier.issn0945-6317-
dc.identifier.urihttp://hdl.handle.net/10371/77662-
dc.description.abstractGastric carcinoma (GC) is one of the human cancers in which promoter CpG island hypermethylation is frequently found. CpG island methylator phenotype (CIMP) refers to a subset of GCs which harbor concordant methylation of multiple promoter CpG island loci. However, little is known regarding clinicopathological features of CIMP-positive (CIMP-high) GC. Our study aimed to characterize clinicopathological features of CIMP-high GC. We analyzed 196 cases of GCs for their methylation status in 16 cancer-specific CpG island loci using MethyLight assay and arbitrarily defined CIMP-high GC as those with methylation at 13 or more CpG island loci. With exclusion of microsatellite instability-positive GC and EBV-positive GC from the analysis, CIMP-high GC (n = 10, 6.7%) demonstrated tendency toward higher cancer stage, infiltrative growth type, poor differentiation, and diffuse or mixed type of Lauren classification. CIMP-high GC showed significantly shortened survival compared with that of CIMP-negative GC. When CIMP-negative GC (methylation at 12 or less) was divided into CIMP-intermediate and CIMP-low (methylation at one or none), CIMP-low exhibited better clinical outcome than CIMP-intermediate. Hypermethylation at 14 CpG island loci or more was closely associated with poor clinical outcome and found to be an independent prognostic factor. Our findings that CIMP-high GCs were featured with characteristic clinicopathological parameters, including poor prognosis are distinct from previous studies. More extensive, large-scaled study is necessary to validate the findings of the present study.ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectCpG islandko_KR
dc.subjectCpG island methylator phenotypeko_KR
dc.subjectGastric cancerko_KR
dc.subjectMethylationko_KR
dc.titleCpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological featuresko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor박석윤-
dc.contributor.AlternativeAuthor국명철-
dc.contributor.AlternativeAuthor김영우-
dc.contributor.AlternativeAuthor조남윤-
dc.contributor.AlternativeAuthor정남희-
dc.contributor.AlternativeAuthor권형주-
dc.contributor.AlternativeAuthor김태유-
dc.contributor.AlternativeAuthor강경훈-
dc.identifier.doi10.1007/s00428-010-0962-0-
dc.citation.journaltitleVIRCHOWS ARCHIV-
dc.description.citedreferencePark SY, 2010, VIRCHOWS ARCH, V456, P625, DOI 10.1007/s00428-010-0916-6-
dc.description.citedreferenceKim JH, 2009, VIRCHOWS ARCH, V455, P485, DOI 10.1007/s00428-009-0857-0-
dc.description.citedreferencePark SY, 2009, J PATHOL, V219, P410, DOI 10.1002/path.2596-
dc.description.citedreferenceYoo EJ, 2008, VIRCHOWS ARCH, V452, P515, DOI 10.1007/s00428-008-0596-7-
dc.description.citedreferenceKang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707-
dc.description.citedreferenceOgino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082-
dc.description.citedreferenceEnomoto S, 2007, CANCER SCI, V98, P1853, DOI 10.1111/j.1349-7006.2007.00625.x-
dc.description.citedreferenceGoel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018-
dc.description.citedreferenceWeisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834-
dc.description.citedreferenceOgino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933-
dc.description.citedreferenceChang MS, 2006, CLIN CANCER RES, V12, P2995, DOI 10.1158/1078-0432.CCR-05-1601-
dc.description.citedreferenceOgino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135-
dc.description.citedreferenceKusano M, 2006, CANCER, V106, P1467, DOI 10.1002/cncr.21789-
dc.description.citedreferenceChan AOO, 2006, GUT, V55, P463, DOI 10.1136/gut.2005.077776-
dc.description.citedreferenceAn CH, 2005, CLIN CANCER RES, V11, P656-
dc.description.citedreferenceOue N, 2003, CANCER SCI, V94, P901-
dc.description.citedreferenceChan AOO, 2003, GUT, V52, P502-
dc.description.citedreferenceKang GH, 2002, AM J PATHOL, V160, P787-
dc.description.citedreferenceToyota M, 1999, CANCER RES, V59, P5438-
dc.description.citedreferenceToyota M, 1999, P NATL ACAD SCI USA, V96, P8681-
dc.description.citedreferenceBoland CR, 1998, CANCER RES, V58, P5248-
dc.description.tc3-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse